Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. - Wikidata - awgldk - TriplyDB

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

http://www.wikidata.org/entity/Q35042985

about

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway TGF-β signaling and its targeting for glioma treatment WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration.Role of Nitric Oxide in Glioblastoma Therapy: Another Step to Resolve the Terrible Puzzle ?The roles of TGFβ in the tumour microenvironment.Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.The interconnectedness of cancer cell signaling.LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.Recent developments on immunotherapy for brain cancer.Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.Aligned chitosan-polycaprolactone polyblend nanofibers promote the migration of glioblastoma cells.Cancer subclonal genetic architecture as a key to personalized medicine.Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor.Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma.Novel approaches to glioma drug design and drug screening.Transforming growth factor-beta and its implication in the malignancy of gliomas.Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.New tricks for an old fox: impact of TGFβ on the DNA damage response and genomic stability.Molecular targets in glioblastoma.Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment.Transforming growth factor-β: A therapeutic target for cancer.Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma.Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas.Induction of transient tenogenic phenotype of high-density cultured human dermal fibroblasts.

P2860

Q26797238-15B9920E-EA27-437E-988D-66EEFA6D0CD2 Q28082042-DC706F90-DBBC-4B8A-B263-213E9B1BB26B Q30572906-A1A625E0-499E-46F4-A6DA-EED708587BF6 Q33361853-55A3E4E5-D298-4824-ADE2-28C6326E9A16 Q33630845-DC468CBB-12EB-4D4B-BB87-87AA7ABB0643 Q33912275-E2A3356D-F438-42E3-BC8B-FC02E803DB16 Q35289038-370B96E6-B9CD-4036-80C4-6C8F0A1D87E3 Q35669733-CBC01715-E9A2-4FA6-85FC-B814471F50BC Q35854002-7E8F7D91-6A7E-46FC-9B0B-AF9EBB281462 Q35992355-0495F372-9A82-4CCE-9449-7AC44287214B Q36511945-DF730F40-E9D2-4263-BEFD-5E070F38DBBC Q37048061-3958DEF6-D144-4A9F-BB88-2CEB1E0A60CA Q37384592-084B60C7-8A25-4634-B706-7A566F462A5D Q37448116-4934A28C-7650-49F5-BA31-75839432047E Q37503365-E1DD3B19-35FE-4B33-9214-88BB2BF6182A Q37615676-7ABAFAC2-19C4-42D5-9809-7380A2FAA057 Q37699420-F0F1DE13-F6DE-43D3-9D82-AFEE25AE5D08 Q38112184-3A96DDCB-6349-4B4F-B0A9-7A8BF02E5EEF Q38192972-CB95C155-21BE-4930-8E8A-1CFA47E17AC5 Q38227496-7DAA664B-6A94-4F35-BB70-D226837E6CFC Q38245806-84A91A4F-EC47-4E43-88FA-B92BA3A2E921 Q38465854-FF14D17E-C095-4E81-9ABE-55EF1E09C11C Q38957729-CFD33228-D9EA-4FCE-B591-99DBA0106CF6 Q39071510-5E6E7AE4-8CA8-4868-8622-03B83398E7C7 Q39346505-BCB932D6-F2D4-484F-9F29-52E01A2D963F Q41474996-B9614781-C5DE-4832-889F-D3088449B1A6 Q41879186-59C73B84-BCD5-465B-90FB-099F585FA231 Q44705929-473ED620-CD27-4D21-80C0-8A87AE3AF0FC Q47996105-DA13D92C-BA7A-4A98-B401-08309ACAB22B Q48089996-2747F2CB-B7B9-41F6-8913-742DD913A679 Q52657971-433D3408-75C4-4A1D-9D4C-2C952D7AA7CE

P2860

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

http://www.wikidata.org/entity/Q35042985

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Trimodal glioblastoma treatmen ...... I kinase inhibitor LY2109761.

@en

type

label

Trimodal glioblastoma treatmen ...... I kinase inhibitor LY2109761.

@en

prefLabel

Trimodal glioblastoma treatmen ...... I kinase inhibitor LY2109761.

@en

P1433

Q35042985-1AA90FB9-0FDB-484F-A035-CE482A3F318B

P1476

Q35042985-052BA415-D876-46B0-A348-82BE7383C1C7

P2093

Q35042985-0D6EAE03-64CE-439A-9065-78CBEB1264D9

Q35042985-15D368FA-C83D-4108-B0B2-3B16CBF0D11B

Q35042985-23E503E5-6164-488C-BF03-56D10C292C5B

Q35042985-43B88461-38ED-4B14-93A9-A1C0A4B33CF1

Q35042985-5A2A4B91-3224-4A6B-9A82-8D3C1C53C323

Q35042985-85BA0FD3-AB79-402B-AF46-86BC7F15F33A

Q35042985-A64CC504-3B33-4BF9-AA3B-A11E5A37B697

Q35042985-E23ECD3D-998D-4B25-A01D-4FF924911CB9

Q35042985-F40F6698-F594-4F34-A060-E71A0AE09764

Q35042985-F56F9EAE-E20A-47EC-A158-FB0FEC158435

P2860

Q35042985-08D4B809-7239-4029-B4A4-EA4EA4C6B842

Q35042985-0DCB0A82-CD21-428A-863E-2FA44D5C73F5

Q35042985-1081B929-D67F-489E-A6CC-93471B6D788B

Q35042985-1CEF39DD-F7A0-4984-BC60-FB8CD9F66D1B

Q35042985-2310C9A6-9502-4D0F-88E4-51350444D918

Q35042985-2E97188E-E97E-4AB3-B7C4-E5D774696865

Q35042985-2F13F9E6-FF27-4E5F-A1EC-CA4079385AD9

Q35042985-3089C7FC-62AE-4736-8721-3D298853A74C

Q35042985-30C15203-5BBC-41F3-8DF7-06B3D873E36E

Q35042985-3207892D-5959-49F8-995D-8ADD6DF48AC4

P304

Q35042985-88020D67-C389-47EC-89A6-D15D56B4EBBD

P31

Q35042985-9D5996D1-3476-4D48-AC23-700F243FD7C6

P356

Q35042985-972E9E26-5797-4DAC-9D73-B1A93A664ED9

P433

Q35042985-8596B6D4-1043-40D5-BCF3-A5A809E3C3FA

P478

Q35042985-267DF485-9944-4981-985A-F715AD1C3785

P577

Q35042985-5E09CA39-1A00-4C9F-B3FB-BD42C4F32EA4

P5875

Q35042985-FEC75DC7-C279-43A9-874D-BB989F82F17E

P698

Q35042985-6BCF1D67-9900-4FCD-836E-4A8C4C9EFEC4

P921

Q35042985-FA4B95C4-F948-42BB-9D2B-ECB17BC73198

P932

Q35042985-298C661F-19DE-4C79-BC9C-46F044EB1FFA

P356

P1433

P1476

Trimodal glioblastoma treatmen ...... I kinase inhibitor LY2109761.

@en

P2093

Carmen Timke

http://www.w3.org/2001/XMLSchema#string

Kai Hauser

http://www.w3.org/2001/XMLSchema#string

Klaus J Weber

http://www.w3.org/2001/XMLSchema#string

Mengxian Zhang

http://www.w3.org/2001/XMLSchema#string

Michael Lahn

http://www.w3.org/2001/XMLSchema#string

Na Han

http://www.w3.org/2001/XMLSchema#string

Peter E Huber

http://www.w3.org/2001/XMLSchema#string

Peter Peschke

http://www.w3.org/2001/XMLSchema#string

Tobias W Herion

http://www.w3.org/2001/XMLSchema#string

Ute Wirkner

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

Escaping from the TGFbeta anti-proliferative control

TGFbeta in Cancer

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro.

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.

Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

P304

537-549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.11258

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51223608

http://www.w3.org/2001/XMLSchema#string

P698

21677877

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3114247

http://www.w3.org/2001/XMLSchema#string